- Home
- NGNE vs OACC Comparison
NGNE vs OACC Comparison
Compare NGNE & OACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OACC
- Stock Information
- Founded
- NGNE 2003
- OACC 2024
- Country
- NGNE United States
- OACC United States
- Employees
- NGNE N/A
- OACC N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OACC
- Sector
- NGNE Health Care
- OACC
- Exchange
- NGNE Nasdaq
- OACC NYSE
- Market Cap
- NGNE 251.9M
- OACC 256.3M
- IPO Year
- NGNE N/A
- OACC 2024
- Fundamental
- Price
- NGNE $15.42
- OACC $10.45
- Analyst Decision
- NGNE Strong Buy
- OACC
- Analyst Count
- NGNE 7
- OACC 0
- Target Price
- NGNE $41.86
- OACC N/A
- AVG Volume (30 Days)
- NGNE 193.9K
- OACC 68.7K
- Earning Date
- NGNE 08-08-2025
- OACC 01-01-0001
- Dividend Yield
- NGNE N/A
- OACC N/A
- EPS Growth
- NGNE N/A
- OACC N/A
- EPS
- NGNE N/A
- OACC N/A
- Revenue
- NGNE $925,000.00
- OACC N/A
- Revenue This Year
- NGNE N/A
- OACC N/A
- Revenue Next Year
- NGNE N/A
- OACC N/A
- P/E Ratio
- NGNE N/A
- OACC $96.91
- Revenue Growth
- NGNE N/A
- OACC N/A
- 52 Week Low
- NGNE $6.88
- OACC $9.95
- 52 Week High
- NGNE $74.49
- OACC $10.85
- Technical
- Relative Strength Index (RSI)
- NGNE 40.98
- OACC N/A
- Support Level
- NGNE $19.13
- OACC N/A
- Resistance Level
- NGNE $18.21
- OACC N/A
- Average True Range (ATR)
- NGNE 1.59
- OACC 0.00
- MACD
- NGNE -0.59
- OACC 0.00
- Stochastic Oscillator
- NGNE 4.26
- OACC 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About OACC OAKTREE ACQUISITION CORP III LIFE S
Oaktree Acquisition Corp III Life Sciences is a blank check company.